We are live on
!
Find out more
SCM
Sarissa Capital Management Portfolio holdings
AUM
$178M
1-Year Est. Return
118.43%
This Fund
S&P 500
This Quarter
Est. Return
+9.33%
1 Year Est. Return
+118.43%
3 Year Est. Return
+79.96%
5 Year Est. Return
+93.71%
10 Year Est. Return
+781.26%
AUM
$499M
AUM Growth
+$66.6M
(+15%)
Cap. Flow
+$32M
Cap. Flow
% of AUM
6.41%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
–
Increased
3
Reduced
–
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$13.5M |
| 2 |
Innoviva
INVA
|
+$13.1M |
| 3 |
SHPG
Shire pic
SHPG
|
+$7.26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$1.85M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biogen
BIIB
$32.2B
| $134M | 26.87% |
461,858
+48,000
| +12% | +$13.5M |
|
|
MDCO
2
DELISTED
Medicines Co
MDCO
| $70.5M | 14.14% |
1,922,000
| – | – |
|
3
Ironwood Pharmaceuticals
IRWD
$724M
| $64.4M | 12.91% |
4,020,317
| – | – |
|
|
4
Innoviva
INVA
$1.53B
| $62.6M | 12.55% |
4,535,000
+874,295
| +24% | +$13.1M |
|
|
AGN
5
DELISTED
Allergan plc
AGN
| $57.4M | 11.5% |
344,000
| – | – |
|
|
ICPT
6
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $53.3M | 10.69% |
635,300
| – | – |
|
|
SHPG
7
DELISTED
Shire pic
SHPG
| $52.2M | 10.46% |
309,000
+45,000
| +17% | +$7.26M |
|
|
NVLN
8
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $3.77M | 0.76% |
1,025,000
| – | – |
|
|
SEEL
9
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $564K | 0.11% |
13
| – | – |
|
10
AbbVie
ABBV
$463B
| $92K | 0.02% |
1,000
| – | – |
|
|
ACHN
11
DELISTED
Achillion Pharmaceuticals
ACHN
| – | – |
-500,000
| Closed | -$1.85M |
|
Similar funds
FC
RP
BC
MG
CSI
SCS
NCG
RE
Sarissa Capital Management's Q2 2018 Portfolio in Review
As of Q2 2018, Sarissa Capital Management held 11 positions worth $499M, up 15% from $432M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Sarissa Capital Management deployed $32M of net new capital in Q2 2018, adding to 3 existing holdings.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the most notable exit was Achillion Pharmaceuticals, an estimated $1.85M sold.
- Sarissa Capital Management added most to Biogen in Q2 2018, an estimated $13.5M increase.
- Sarissa Capital Management fully exited Achillion Pharmaceuticals in Q2 2018, selling an estimated $1.85M.
- Sarissa Capital Management's ten largest holdings make up 100% of its $499M portfolio in Q2 2018.
- Sarissa Capital Management opened 0 new positions and closed 1 in Q2 2018.
- Sarissa Capital Management's portfolio value rose 15% quarter-over-quarter to $499M.
Based on Sarissa Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.